Designation is for treating retinitis pigmentosa, one of the most common types of inherited retinal disorders characterized by the loss of photoreceptor cells OpCT-001 is an iPSC-derived investigational cell therapy being clinically tested to treat retinitis pigmentosa Berlin, Germany, and Cambridge, MA, USA January 22, 2026 – Bayer AG and its wholly owned, independently […]
Berlin, Germany, and Cambridge, MA, USA July 8, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the first patient received the investigational therapy in CLARICO, a Phase 1/2a clinical […]
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD Dr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy. Podcast produced by Foundation […]
Berlin, Germany, and Cambridge, MA, USA February 27, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for […]
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision […]
Collaboration will add a new multigene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness CAMBRIDGE, MA USA and COLUMBIA, MD, March […]
First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021 Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in […]
CAMBRIDGE, Mass., and MADISON, Wis., May 17, 2021 /PRNewswire/ — BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture […]
